Reference Intervals by Age/Sex, N, Median Conc (ng/l) Specimen Type. Non-Heart Failure n = 890 (465 F, 425 M) <45 75+y.

Transcription

1 B, NT-proB, and MR-proA Assays: Analytical Characteristics Designated by Manufacturer IFCC Committee on Clinical Applications of Cardiac Bio-Markers (C-CB) v Company/Platform/ Assay LoD () %CV near LoD or LoQ (Conc, ) Upper Reference Limit (URL); Age, Conc () %CV at URL Reference Intervals by Sex () Reference Intervals by Age/Sex, N, Median Conc () Specimen Type Capture Antibody Detection Antibody Standard Material POC Package Insert: Version Date Abbott /ARCHITECT i systems/ ARCHITECT B % n-heart Failure n = 890 (465 F, 425 M) <45 75+y Anti-B (106.3) mouse Anti-B (BC203) mouse World Wide excluding Japan / /15/R05revised vember 2015 Abbott/i-STAT/B Analytical data from CTI sheet and internally 95 th %: whole blood or Shinogi: BC203 2 Diatec Mouse anti-human B clone: 106:3sc128 3 Synthetic B (Peptide International, Louisville, KY, Cat# 4212v) US, Rev. Date: 01-Jul- 13 biomerieux/vidas/ NT-proB <20 Age <75y n = 319 Mean: 204 SD: 905 Median: <20 95 th : 174 %<cutoff: 92% Age 75y n = 92 Mean: 165 SD: 137 Median: < th : 469 %<cutoff: 95% heparin 14708D US 2015/01 ET Healthcare/Pylon/B 10 20% %, whole blood B aa Single epitope Glycosylated prob China 2016 Fujirebio/Lumipulse G G1200 and G600II/B LoQ = with CV of 10% Sensitivity & specificity at universal cut-off of 100 calculated together with assay specific cut-off of ND Female non-hf median by age: Male non-hf median by age: Females, non-hf by age range: <45 yrs n= n= n= n=250 >75 yrs n= 177 Males, non-hf by age range: <45 yrs n= n= n= n=120 >75 yrs n= 59 Disodium or dipotassium English FRI83445, Apr Ver.02 1

2 Medience (Mitsubishi)/ Pathfast/NT-proB 5 21% 4.7% at % at 450 Male 95% <75y: y: 500 Female 95% <75y: y: 674 Overall n = 578 (324 F, 254 M) <75y: y: 79 Whole blood, NH 2 terminus AB, aa 1-21 AB, aa Synthetic NTproB WW except US and Japan: , Ver.7 US: , Ver.5 Ortho VITROS ECi/EciQ Immunodiagnostic Systems, VITROS 3600 Immunodiagnostic System, VITROS 5600 Integrated System/NT-proB 11 20% <6.0% 242 individuals without CHF (147 F, 95 M) (, heparin) NH 2 terminus, amino acids 1-21, amino acids Synthetic NTproB GEM1315_US_EN, version 8.0, GEM1315_XUS_EN, version 8.0, Quidel/Alere Data t Provided Radiometer/ AQT90 FLEX/ NT-proB th : % n = 497 (248 F, 249 M) Whole Blood (LiHep/ ), (LiHep/ ) NH2 terminus AB, aa 1-21 AB, aa Synthetic Human NT-proB International P Age: <75y n = 123 Mean: SD: 624 Median: th : 200 Response Biomedical/ Ramp/NT-proB LoB: 18 10% at 123 Age: 75y n = 4 Mean: 91.5 SD: 34 Median: th : 138 IFU ,V1.4 % <125: 82% % <450: 100% >75y 75y Response Biomedical/ Ramp/NT-proB LoD: 34 LoB: 27 LoQ: 57 Age: 75y n = 340 Mean: 133 SD: 671 Median: th : 216 IFU US only Age: >75y n = 30 Mean: 450 SD: 811 Median: th : 2447 Roche/proB II/ Modular E170/e411/e601/e602 NT-proB th : 196 e411: 2.6% E170/ e601/e602: 2.7% 254 % <125: 84% % <450: 74% ) AB AB Synthetic NTproB Europe 2

3 Roche/proB II Elecsys STAT e601/e602 NT-proB Roche Elecsys prob II/ e801/18 min.; 9 min. NT-proB th : 196 e601/e602: 2.5% th : min: 2.6%; 9 min: 1.9% : ) ) AB AB AB AB Synthetic NTproB Europe Synthetic NTproB Europe Roche prob II Elecsys 2010/Modular E170/e411/e601/e602 NT-proB 5 95 th <75y: y: 718 e411/ % at % at 2410 E170/ e601/e602: 2.7% Male 95 th <75y: y: 852 Female 95 th <75y: y: 624 n = 1411 (800 F, 611 M) <45 and 75y ) AB AB Synthetic NTproB USA Roche prob II Elecsys STAT e601/e602 NT-proB 5 95 th <75y: y: 718 e601/e % at % at 935 Male 95 th <75y: y: 852 Female 95 th <75y: y: 624 n = 1411 (800 F, 611 M) <45y and 75 y ) AB AB Synthetic NTproB USA Roche CARDIAC NT-proB cobas h232 6* 97.5 th : 196* <15% * 254 * 18-90y* Heparinized venous blood* Synthetic NTproB EU, ATELLICA NT-proB <4% Males, n = 348 <55y: y: y: 73 75y: 119 Females, n = 203 <55y: y: y: 52 75y: 163 (Li Hep ) _ ATELLICA B <3% Overall, n = 1521 <45y: y: y: y: 22 75y: 44 c-terminal ring structure _02, ADVIA Centaur XP/XPT NT-proB 20 LoQ <33 <5.0% Males, n = 348 <55y: y: y: 73 75y: 119 Females, n = 203 <55y: y: y: 52 75y: 163 (Li Hep ) EN Rev.D, ADVIA Centaur CP/XP/XPT B <2 LoQ <5% Overall, n = 1521 <45y: y: y: y: 22 75y: 44 c-terminal ring structure EN Rev.V

4 DIMENSION VISTA P-B (LOCI) NT-proB Dimension VISTA B (OUS only) DIMENSION RXL P-B (HM) NT-proB 0.8 LoQ <30 <5.2% <4.7% 3 LoQ % 10 LoQ <30 <5.6% <5.1% Males, n = 155 <55y: y: y: y: 173 <55y: y: y: 87 75y: 167 Males, n = 736 <45y: y: y: y: 17 75y: 26 Females, n = 785 <45y: y: y: y: 25 75y: 54 Males, n =145 <55y: y: y: 76 75y: 111 <55y: y: y: 59 75y: 131 hep, ) hep, ) c- terminal () ring structure (14-21) Synthetic human B (amino acid ) A PN EN Rev.T, F PN DIMENSION EXL P-B (LOCI) NT-proB 2 LoQ <30 <8.9% Males, n = 155 <55y: y: y: y: 173 <55y: y: y: 87 75y: 167 hep, ) C PN IMMULITE/ IMMULITE 1000 Turbo NT-proB % at 52 Overall, n = 217 <75y: 28 75y: th percentile: <75y: y: 589 Heparin PINLSKNT-3[20] IMMULITE/ IMMULITE 2000 NT-proB /Stratus CS Acute care pb test Pack NT-proB % at 35 LoQ (20%CV) at 50 <5% <5% 5.3% <3% Overall, n = 217 <75y: 28 75y: th percentile: <75y: y: 589 Males, n = 145 <55y: y: y: y: 162 <55y: y: y: 81 75y: 167 Heparin Blood sample, Na or Li heparin PIL2KNT-16,

5 Thermo Fisher (BRAHMS)/ Kryptor/ MR-proA Tosoh/AIA B 2.1 pmol/l LoQ <10 pmol/l 120 pmol/l 1.9 LoQ <6.5% 2.9% at th percentile: 85.2 pmol/l; Median 46.1 (nparametric) n = 154 n = 130 (heparin; ) collected in plastic tubes Rat Synthetic pro- A IFU 25/03/2015 EU rev. B LoD, limit of detection; LoB, limit of blank; LoQ, limit of quantitation;, not provided; M, male, F, female; Conc, concentration; POC, point of care; AB,. Assays listed in blue were abstracted from the manufacturers package inserts as the manufacturer did not respond to IFCC C-CB request to complete table. 5